Theragnostic Platform

Theragnostics is a patient management strategy involving the integration of diagnostics and therapeutics. AAA is a pioneer in the field of nuclear medicine theragnostics, with an expanding pipeline of theragnostic pairings for various oncology indications.

In the context of nuclear medicine, theragnostics refers to the use of molecular targeting molecules labeled either with diagnostic radionuclides (e.g., positron or gamma emitters), or with therapeutic radionuclides (e.g., beta emitters) for diagnosis and therapy of a particular disease. Our platform is based upon radiolabeling a targeting molecule, with high affinity for a receptor expressed on a tumor cell, with either gallium Ga-68 for diagnostic use, or lutetium Lu-177 for therapeutic purposes. Therefore, molecular imaging and diagnosis of the disease can be effectively followed by personalized treatment utilizing the same molecular targeting compounds.

Using the same targeting compounds in this manner also enables a more complete approach to patient management, because the diagnostic can then serve several simultaneous functions: diagnosis, restaging, monitoring, selection for therapy using the same molecule labeled with a therapeutic radionuclide, or a different treatment course, as well as follo-up after treatment.

For patients, theragnostics can lead to more effective care, tailoring therapeutic intervention to patients who would benefit the most while reducing or eliminating unnecessary treatment. By predicting patients who might not respond to unnecessary treatments or would otherwise experience side effects, a theragnostic approach is both efficient and patient centric.

For physicians, theragnostics can enhance their ability to diagnose and stage disease, select optimal therapies, and monitor treatment response and disease progression, improving prognostic capability for better health outcomes in a safe and effective manner.

For payors, theragnostic approaches can reduce costs associated with suboptimal diagnostics and treatments and shorten the time needed to diagnose and treat patients with effective individualized treatment plans.